Jul 9, 2018

Widely-used blood pressure drug could help treat type 1 diabetes

A diabetic girl injects herself with insulin, the most common diabetes treatment. Photo: Douglas Grundy/Three Lions/Getty

A generic drug meant to address high blood pressure may supplement insulin therapy for people with recent onset type 1 diabetes, according to a new study published Monday in Nature Medicine.

Why it matters: If validated by larger studies, the drug may allow a patient to reduce insulin shots, keep blood sugar levels more stable, and protect important pancreas cells from the disease, which affects roughly 1.25 million Americans.

What they did: The research team tested 24 adults with newly onset type 1 diabetes, with 11 supplementing their insulin with verapamil and 13 following the insulin regime alone.

What they found: The authors found that verapamil with the insulin regime helps preserve the pancreas cells that naturally produce insulin (beta cells), lessening the amount of added insulin needed as the disease progressed, while also helping stabilize blood sugar levels.

The study is one of the first to target the cell function side of type 1 diabetes (T1D), which is important, according to David Harlan, co-director of the Diabetes Center for Excellence at UMass Medical School.

  • He says, "99% of research over the past 40 years has focused on the immune system side" rather than targeting beta cells.
  • Harlan, who was not part of the study, also emphasized the safety of the drug:
"There's always a risk/benefit analysis in diabetes treatment because as bad as T1D is as a disease, with modern therapies the prognosis is outstanding. New treatments must be safe, and verapamil is a very low risk, safe drug."

Go deeper: Verapamil is already FDA approved for treating hypertension. The research team said they were unable to obtain pharmaceutical funding for their research, so they relied instead upon funding from diabetes nonprofit JDRF.

"The [pharmaceutical] industry has no interest in this drug because it's generic and kind of cheap...As much as this helps patients, there is no money to be made."
— Study author Anath Shalev to Axios

The bottom line:

  • Because the drug has already been determined to be safe, physicians could theoretically prescribe verapamil now for diabetes treatment off label.
  • Shalev hopes there will be more trials in larger populations, particularly in children and patients who've had diabetes for a longer time but have retained some ability to produce insulin.
  • Harlan said patients with type 2 diabetes, many of whom already have hypertension, could experience dual benefits of verapamil.

Yes, but: The study only involved 24 patients over a year and was only tried on patients who had new onset type 1 diabetes. The authors said larger studies are needed before the medication should be used more widely to treat diabetes.

Go deeper

Hospitals are starting to get their coronavirus cash infusion

Illustration: Rebecca Zisser/Axios

The federal government is sending $64 billion to hospitals, post-acute facilities and other medical providers to help cope with the coronavirus fallout.

Yes, but: Even though more funding is coming, safety net and rural hospitals fear they are getting a raw deal from the way some of the money is being distributed.

Biden, Sanders work toward truce on big issues

Photo: Mandel Ngan/AFP via Getty Images

Joe Biden isn’t about to become Bernie Sanders, but he’s signaling that there’s potential for more common ground on issues such as health care, student debt, climate change and more in the weeks ahead.

What to watch: As Biden courts Sanders' endorsement, their teams will hold policy discussions in the next few weeks with the expectation that Biden will incorporate some elements of Sanders' agenda, a person familiar with those plans tells Axios.

Some Trump aides eye May 1 start to coronavirus reopening

President Trump was flanked at yesterday's briefing by HHS Secretary Alex Azar (far left), Vice President Pence and Dr. Deborah Birx. Photo: Win McNamee/Getty Images

President Trump's aides, encouraged by virus data showing fewer deaths than once projected, are working behind the scenes to deliver on his vow to reopen America "sooner rather than later."

What to watch for: The official said there’s a lot of internal energy pushing for May 1, because that's the end of the White House's "30 days to slow the spread."